{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:42:09Z","timestamp":1787668929407,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016925","name":"Takeda Foundation","doi-asserted-by":"publisher","award":["Vedo IISR -2015-101086"],"award-info":[{"award-number":["Vedo IISR -2015-101086"]}],"id":[{"id":"10.13039\/100016925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Combining vedolizumab with a rapid-onset drug such as cyclosporine is a novel combination treatment for severe steroid-resistant ulcerative colitis (UC). This prospective study describes the efficacy and safety of cyclosporine in conjunction with vedolizumab in patients with severe, steroid-resistant UC with 1 year of follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Seventeen steroid-resistant UC patients were treated with cyclosporine in combination with vedolizumab, with a follow up of 52 weeks. Clinical and endoscopic response, remission rates, and colectomy-free survival were the primary endpoints. Secondary endpoints included biochemical response and remission with C-reactive protein, erythrocyte sedimentation rate, and fecal calprotectin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifteen (88%) of 17 patients initially responded to cyclosporine and were started on vedolizumab. By week 10, 11 (73%) of 15 patients had achieved endoscopic remission with a Mayo score of \u22641. At week 26, 14 (93%) of 15 of the patients were in clinical remission and 11 (73%) were in endoscopic remission. At week 52 of follow-up, 10 (71%) of 14 of these patients continued to be in endoscopic remission and 11 (79%) of 14 were in clinical remission. Among the 10 patients in endoscopic remission, 8 (80%) reached histological remission. Colectomy-free survival rate was 82% (n = 14 of 17) at 1 year and mean C-reactive protein, erythrocyte sedimentation rate, and fecal calprotectin levels were 3.2\u00a0mg\/L, 16.1\u00a0mm\/h, and 168.3 \u00b5g\/g, respectively. No serious adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Bridging cyclosporine to vedolizumab in severe, steroid-refractory UC patients is effective and safe at inducing and maintaining clinical, endoscopic, and biochemical response and remission up to 52 weeks of follow-up. Larger prospective studies are warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izab328","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T22:04:33Z","timestamp":1643148273000},"page":"1549-1554","source":"Crossref","is-referenced-by-count":27,"title":["A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab"],"prefix":"10.1093","volume":"28","author":[{"given":"Dino","family":"Tarabar","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, KBC Dr. Dragisa Misovic , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"El Jurdi","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9868-3687","authenticated-orcid":false,"given":"Cindy","family":"Traboulsi","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Yvellez","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Milenkovic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Military Medical Academy , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanko","family":"Petrovic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Military Medical Academy , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojana","family":"Subotic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Military Medical Academy , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Gils","sequence":"additional","affiliation":[{"name":"Laboratory for Therapeutic and Diagnostic Antibodies Department of Pharmaceutical Sciences, KU Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Brocic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Military Medical Academy , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Brcerevic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Military Medical Academy , Belgrade , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olgica","family":"Latinovic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Clinical Center Vojvodina , Novi Sad , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Jocic","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Clinical Center Vojvodina , Novi Sad , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"2023112212505383100_CIT0001","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults.","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2023112212505383100_CIT0002","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management.","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol."},{"key":"2023112212505383100_CIT0003","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060","article-title":"Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease.","volume":"17","author":"Christensen","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112212505383100_CIT0004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ibd.20363","article-title":"Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine.","volume":"15","author":"Lichtiger","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2023112212505383100_CIT0005","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy.","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med."},{"key":"2023112212505383100_CIT0006","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet."},{"key":"2023112212505383100_CIT0007","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/ecco-jcc\/jjz032","article-title":"Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe.","volume":"13","author":"Weisshof","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2023112212505383100_CIT0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis.","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology."},{"key":"2023112212505383100_CIT0009","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience.","volume":"94","author":"Cohen","year":"1999","journal-title":"Am J Gastroenterol."},{"key":"2023112212505383100_CIT0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis.","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"2023112212505383100_CIT0011","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/ibd\/izx067","article-title":"Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety.","volume":"24","author":"Christensen","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2023112212505383100_CIT0012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/ecco-jcc\/jjx179","article-title":"New promising combo therapy in inflammatory bowel diseases refractory to anti-TNF agents: cyclosporine plus vedolizumab.","volume":"12","author":"Sz\u00e1nt\u00f3","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2023112212505383100_CIT0013","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cgh.2018.08.081","article-title":"Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis.","volume":"17","author":"Pellet","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112212505383100_CIT0014","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apt.15616","article-title":"Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.","volume":"51","author":"Ollech","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112212505383100_CIT0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology."},{"key":"2023112212505383100_CIT0016","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs.","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Rev Anti Infect Ther."},{"key":"2023112212505383100_CIT0017","first-page":"189","article-title":"Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.","volume":"4","author":"Behnam","year":"2005","journal-title":"J Drugs Dermatol."},{"key":"2023112212505383100_CIT0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.MIB.0000437497.07181.05","article-title":"Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.","volume":"20","author":"Nelson","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2023112212505383100_CIT0019","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/2050640619873784","article-title":"Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.","volume":"7","author":"Guidi","year":"2019","journal-title":"United European Gastroenterol J."},{"key":"2023112212505383100_CIT0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MEG.0000000000001356","article-title":"Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.","volume":"31","author":"Liefferinckx","year":"2019","journal-title":"Eur J Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izab328\/42272366\/izab328.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/10\/1549\/53679312\/izab328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/10\/1549\/53679312\/izab328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:32:30Z","timestamp":1700674350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/10\/1549\/6515101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,1,25]]},"published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab328","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,1,25]]}}}